Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia. The present study investigated whether or not an optimal dose of aripiprazole could be predicted from these concentrations at week 1.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ther Drug Monit

Title: Therapeutic drug monitoring

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1536-3694

ISSN (Print): 0163-4356

Publication date (Electronic): February 2017

Volume: 39

Issue: 1

Affiliations

[1 ] Departments of *Neuropsychiatry and †Hospital Pharmacy, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan.

Article

DOI: 10.1097/FTD.0000000000000358

PubMed ID: 27861318

SO-VID: 57a16c83-2758-4759-9a04-a825b3f3cb79

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by